• Explore /
  • Poster
  • / High dose bolus (HDB) interleukin-2 (IL2) and concurrent low dose ipilimumab followed sequentially by nivolumab in patients with advanced melanoma after failure of anti-PD1-based immunotherapy and BRAF-MEK inhibition.

High dose bolus (HDB) interleukin-2 (IL2) and concurrent low dose ipilimumab followed sequentially by nivolumab in patients with advanced melanoma after failure of anti-PD1-based immunotherapy and BRAF-MEK inhibition.

Abstract Poster

Authors

Ahmad Tarhini

Ahmad A. Tarhini

Departments of Cutaneous Oncology and Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Ahmad A. Tarhini , Zeynep Eroglu , Mariem Galuia , Islam Eljilany , Denise Kalos , Michael J Schell , Leticia Tetteh , Edith Abraham , Allison Richards , Andrew Scott Brohl , Nikhil I. Khushalani , Joseph Markowitz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT04562129

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 9543)

DOI

10.1200/JCO.2024.42.16_suppl.9543

Abstract #

9543

Poster Bd #

327

Abstract Disclosures

Similar Posters

First Author: Yu Chen

First Author: Julie Williamson

First Author: Paolo Antonio Ascierto

First Author: Geoffrey Thomas Gibney